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Autism spectrum disorder (ASD) is one of the most common neurodevelopmental dis orders, but effective medical treatments for the core symptoms of the disorder are still lack ing. According to the Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM5), the core symptoms of ASD comprise deficits in social communication and inter action, and repetitive and restricted behaviours, which include sensory abnormalities. Novel genetic and preclinical approaches now pro vide unprecedented opportunities to identify the underpinning pathophysiological mecha nisms and aetiologybased treatment targets, as discussed in a Review article by Ghosh et al. (Drug discovery for autism spectrum dis order: challenges and opportunities. Nat. Rev. Drug Discov. 12, 777-790 (2013)) 1 . This has led to more interest from the pharmaceutical indus try in an area in which the overall risk of failure is seen as very high because key par ameters of drug efficiency are not yet established and the regulatory environment is uncertain. For exam ple, industry has recently invested in several precompetitive projects, such as the European Union (EU) Innovative Medicines Initiative (IMI)brokered public-private partnership EUAIMS (European Autism Inter ventions -A Multicentre Study for Developing New Medications) 2 . However, even when new compounds that show preclinical promise for ASD are found, there are still considerable challenges in test ing them in clinical trials. For instance, the current practice of testing treatments in clini cally and biologically heterogeneous patient groups hampers the ability of investigators to detect potentially significant efficacy sig nals in specific subgroups who 'respond' . There fore, we need biomarkers that stratify patient populations according to distinct biological subtypes. So far, the identification and valid ation of biomarkers has been limited by studies with small sample sizes that have insufficient power and/or because studies use different (and often not standardized) meas ures. We also need quantifiable, reproducible outcome measures -including surrogate end points -that are sensitive to change, in order to assess treatment efficacy.
Currently, the EUAIMS Longitudinal European Autism Project (LEAP) is the world wide largest multicentre, multidisciplinary study to identify stratification biomarkers for ASD and biomarkers that may serve as surro gate end points. In total, the study will include approximately 450 individuals with ASD between the ages of 6 and 30 years, and 350 control participants with typical development or mild intellectual disabilities. All participants are comprehensively characterized in terms of their clinical symptom profile, comorbidities, quality of life, level of adaptive function, neuro cognitive profile, brain structure and function (assessed using structural magnetic resonance imaging (sMRI), functional MRI (fMRI) and electroencephalogram (EEG)), biochemi cal biomarkers, prenatal environmental risk factors and genomics (see Supplementary information S1 (table) ).
To understand whether data generated in this study would be accepted in regulatory decisions for future clinical trials, the LEAP Group obtained scientific qualification advice from the European Medicines Agency (EMA) on the population selection criteria, clinical end points and biomarker methodologies to be used. The EMA's Committee for Medicinal Products for Human Use (CHMP) offers tailored advice to support the qualification of innovative methods that have been developed for a specific intended use in the context of research into and development of pharma ceuticals. The goal of using qualified meth ods is to enable a more robust assessment of risks versus benefits in clinical trials. Another advantage of the procedure of qualifying these methods is that, once qualified, these clini cal study instruments may be applied by any investigator in subsequent clinical research, thus ensuring greater scientific rigour.
Population selection criteria
The CHMP agreed to following the DSM5 criteria for a diagnosis of ASD and stressed the use of the 'clinical specifiers' , such as cog nitive ability, symptom severity, association with a known medical or genetic condition or environmental factors. Reaching ASD cutoffs on 'goldstandard' clinical instruments, such as the Autism Diagnostic InterviewRevised and the Autism Diagnostic Observation Schedule, was not considered necessary for participant inclusion. Instead, comparison between participants who do versus those who do not reach the cutoff on these meas ures may help to ascertain whether a par ticular biomarker extends to the 'broader' autism spectrum. Inclusion of nearly all psy chiatric comorbidities was agreed on, as up to 70% of people with ASD have one or more comorbid conditions, such as attentiondefi cit hyperactivity disorder (ADHD), anxiety or depression 3 . Two exceptions are psychosis and bipolar disorder, as they represent severe psychiatric illnesses that typically require care ful medical management, which may interfere with participation in research studies.
The CHMP also supported the inclusion of people with ASD and mild intellectual disabilities (as defined by an IQ below 70 ± 5 and low adaptive behaviour). So far, the vast majority of biomarker studies has focused on highfunctioning individuals with ASD, even though approximately 55% of individuals with ASD have mildtosevere intellectual disabili ties 4 . Therefore, relatively little is known about cognitive or neurobiological biomarkers in the patient group that tends to have the poorest outcome and for whom medical treatments are arguably particularly urgent. Likewise, the inclusion of participants on stable medication (that is, lasting more than 10 weeks) was also accepted. The reality is that 30-70% of patients with ASD are prescribed at least one medica tion to treat associated symptoms. Finally, as a reasonably stable ASD diagnosis can be made from the age of 2-3 years onwards, and as a number of assessment tools used in the LEAP have been validated for use in children from the age of 4 years, the CHMP stressed the importance of also identifying and validat ing biomarkers across the preschool age range (that is, below 6 years of age).
Clinical outcomes
All of the proposed clinical scales (see Supplementary information S1 (table)) were accepted as clinical outcomes. These scales are not to be used to validate diagnosis, how ever, as the specificity of many is limited. Indeed, several recent frameworks, including the US National Institute of Mental Health Research Domain Criteria, now recognize that abnormalities in many fundamental behavioural dimensions probably cut across distinct, categorically defined psychiatric disorders 5 . This implies that instruments probing for those behaviours will inevit ably have less than 100% specificity. It is also possible that future treatments will be aimed at symptoms or cognitive or neural system domains that may be shared between diagnostic categories.
A major priority for the LEAP was the need to define cutoffs for each clinical instrument that represent clinically meaningful changes.
Cutoffs can be determined by testing whether changes in symptom severity from base line to followup predict functional changes in quality of life or adaptive behaviour. For instance, changes in functional scores that are smaller than 0.25 standard deviations may be considered too small to have clinical relevance, whereas an improvement by a full stand ard deviation may be considered 'clinically significant' (REF. 6 ).
Biomarker stratification approaches
The CHMP agreed to the testing of all the pro posed methodologies (including cognitive, eye tracking, EEG, brainimaging and biochemical markers) as potentially enriching biomarkers. However, the goal of identifying ASD sub groups that are more biologically homogene ous requires novel stratification approaches that go beyond the predominant focus on case-control differences (FIG. 1) .
First, individuals are stratified by popu lation criteria, such as comorbidities or sex. For example, sex differences both in typical development and in ASD have been reported at multiple levels, including in serum biomark ers, in brain structure and function, and in sev eral aspects of cognition 7 . Given the strong sex bias towards males in ASD, we are selectively overrecruiting females to identify potentially sexspecific biomarkers.
Second, based on an accelerated longi tudinal design, we aim to establish whether some ASD biomarkers may only be detect able at certain developmental stages. This involves first constructing crosssectional developmental trajectories for each measure (for example, performance on a cognitive task or brain anatomical indices) in the typically developing (TD) group. Confidence intervals around the TD trajectory will then be used to assess, for each individual with ASD, whether they fall outside the range of performance expected for their age group. On this basis, cutoffs for stratification biomarkers can be established for a particular developmental level. To test the stability of and changes in a biomarker over time, the crosssectional tra jectories will be validated by the longitudinal followup data.
Third, we will use multivariate and multi modal approaches to divide individuals into groups according to differences in brain devel opment and function that underpin key cog nitive systems. fMRI studies have delineated regional functional activation and connectivity differences in individuals with ASD when per forming certain cognitive tasks or during rest ing state. Substantial variability (for ex ample, in hypoconnectivity versus hyperconnect ivity patterns in individuals with ASD), both among studies and among individuals within studies, may indicate substantial heterogene ity among individuals with ASD. The large cohort of the LEAP will allow us to delineate ASD subgroups using multivariate pattern classification approaches based on profiles The authors also acknowledge members of the EU-AIMS LEAP Group (see Supplementary information S2 (box)). E.L. and W.S. contributed equally to this work, and J.K.B. and D.G.M.M. contributed equally to this work. *The views expressed in this article are the personal views of the author and may not be understood nor quoted as being made on behalf of or reflecting the position of the European Medicines Agency (EMA) or one of its committees or working parties or any of the national agencies. of brain structure 8 and function 9 and relate them to clinical outcome. Neuroimaging techniques also help us to identify the mecha nisms through which interventions improve functioning. Recent eventrelated potential and pharmacological fMRI 10 studies have been used to ascertain whether treatment effects are reached because of the normalization of atypical neural processes, or owing to the development of compensatory mechanisms.
Last, molecular biomarkers will be crucial in predicting treatment response. Networkbased stratification approaches have recently been successfully used in cancer research to identify tumour subtypes. We will use similar approaches to identify molecular ASD subgroups on the basis of the entire genetic mutation profile. We then aim to map these molecular groups, from the 'bottom up' , to neurobiological biomarkers and clinical symptom profiles.
Conclusions
The CHMP's key recommendations on the LEAP study design and biomarker approaches included the need to establish sensitivity and specificity for all candidate biomarkers and to define cutoffs for quantitative stratification markers. The CHMP also highlighted the need to establish, for each candidate biomarker, how abnormalities map on to differences in prog nosis, and to define what would be considered neuroimaging biomarkers that combine different indices of, for example, brain structure and connectivity, as derived from structural magnetic resonance imaging (sMRI), functional MRI (fMRI) and diffusion tensor imaging (DTI). Different subgroups are then mapped on to potentially shared versus potentially distinct clinical profiles. For example, clinical profile A may be characterized by particular sensory abnormalities, whereas clinical profile B may be characterized by a pattern of particular socialcommunicative deficits. c | Subgroups can be identified according to differences in their genetic-molecular profile. These stratified groups can then be compared with one another in terms of biochemical biomarkers, brain structure and function, cognition and clinical profile. Nature Reviews | Drug Discovery as clinically relevant differences. As this is an exploratory observational study, the large number of end points tested was recognized. To achieve a balance between the risk of false positives and false negatives (if one were to cor rect for the multiplicity of tests), replication in an independent data set will be required. This will be particularly necessary for the validation of any candidate biomarker as a surrogate end point. To facilitate data pooling and replication, we are sharing our protocols and standard oper ating pro cedures with other research groups (for example, the Australian Cooperative Research Centres (CRCs), the French Fondation FondaMental, the Chinese Key 973 pro gramme, the Foun dation for the US National Institutes of Health (FNIH) and the Canadian Province of Ontario Neurodevelopmental Disorders (POND) network). The outcome of this qualification advice process is an important step towards a shared understanding of biomarker criteria for ASD between academia, industry and regulators. Basic science is now at the brink of being able to identify molecular mechanisms and trans late them into effective therapeutic targets for the treatment of individuals with ASD. The validation and qualification of ASD biomark ers will be key to: help to give industry the confidence to carry out the costly largescale clinical trials that are needed to assess the effi cacy and mechanism of therapeutic interven tions; delineate the patient populations that will bene fit from such interventions; and facilitate the regulatory approval of new therapies.
